Background and aims: Atorvastatin is a member of the drug class known as statins, which used as a lipid-lowering agent. The study aim was to assess the effect of atorvastatin on body weight and blood glucose levels among diabetic and non-diabetic patients.
Material and Methods: A 359 hyperlipidemic Jordanian patients using atorvastatin at least for 1 year were divided into two groups: diabetic (DM) and non-diabetic (NDM). The changes in lipid profile, thyroid function test, blood glucose indices as well as body weight were assessed and compared between both groups.
Results: There was no statistical significant (p > 0.05) difference between means of body weight after treatment among DM (85.74 ± 3.56) and NDM (81.75 ± 1.25) groups. Descriptive statistics and mean comparisons before and after atorvastatin treatment, showed statistical significant (p ≤ 0.05) differences in body weight and total cholesterol among NDM group and in total cholesterol and LDL-Ch among DM group. There was an increase in fasting blood glucose (FBG) and glycated hemoglobin A1c (HbA1c) and a decrease in triglycerides among both groups but the difference was not statistically (p > 0.05) significant.
Conclusions: Atorvastatin may increase body weight, fasting blood glucose and HbA1c for diabetic and non-diabetic patients.
1. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 99: 95-112, 2003.
2. National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville (MD): National Center for Health Statistics, 2011.
3. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366: 1267-1278, 2005.
4. Lemaitre RN, Furberg CD, Newman AB. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med 158: 1761-1768, 1998.
5. Heart Protection Study Collaborative Group MRC/BHF. Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360: 7-22, 2002.
6. Walsh JME, Pignone M. Drug treatment for hyperlipidemia in women. JAMA 291: 2243-2252, 2004.
7. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol 159: 169-176, 2012.
8. Pasternak RC, Smith SC, Bairey-Merz CN. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106: 1024-1028, 2002.
9. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. National lipid association statin safety assessment task force. conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol 97: 89-94, 2006.
10. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med 23: 317-324, 2012.
11. Kumai T, Matsumoto N, Koitabashi Y et al. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem 3: 195-201, 2005
12. Ma T, Chang MH, Tien L, Liou YS, Jong GP. The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study. Drugs Aging 29: 45-51, 2012.
13. Jula, A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 287:598-605, 2002.
14. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. Endocr J 52: 369-372, 2005.
15. Kwang KK, Quon MJ, Seungetal HH. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110: 3687-3692, 2004.
16. Gannage-Yared MH, Azar RR, Amm-Azaretal M et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy non-diabetic patients. Metabolism 54: 947-951, 2005.
17. Koh KK, Quon MJ, Han SH. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45: 1649-1653, 2005.
18. Okada K, Maeda N, Kikuchi K, Tatsukawa M, Sawayama Y, Hayashi J. Pravastatin improves insulin resistance in dyslipidemic patients. J Atheroscler Thromb 12: 322-329, 2005.
19. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49: 1881-1892, 2006.
20. Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol 5: 450-459, 2011.
21. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. J Hepatol 41: 690-695, 2005.
22. Golomb BA, Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373-378, 2008.
23. Maki KC, Ridker PM, Brown VW, Grundy SM, Sattar N. An assessment of the statin diabetes safety task force: 2014 update. J Clin Lipidol 8:17-29, 2014.
24. Khleif Y, Hyassat D, Liswi M, Jaddou H, Ajlouni K. Prevalence of myopathy in subjects on statins therapy attending the national center for diabetes, endocrinology and genetic in Jordan. Endocrinol Metab Syndr 4: 204-210, 2015
25. Thrusfield M. Sampling. In: Veterinary epidemiology, second ed. Blackwell Science Ltd, pp 183-185, 1995.
26. Moutzouri E, Liberopoulos E, Mikhailidis DP et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 65: 1141–1148, 2011.
27. Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort. Diabetologia 58: 1109-1117, 2015.
28. Castro MR, Simon G, Cha SS, Yawn BP, Melton LJ, Caraballo PJ. Statin use, diabetes incidence and overall mortality in normoglycemic and impaired fasting glucose patients. J Gen Intern Med 31: 502-508, 2016.
29. Güçlü F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58: 614-618, 2004.
30. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 215: 1-8, 2011.
31. Aguirre L, Hijona E, Macarulla MT et al. Several statins increase body and liver fat accumulation in a model of metabolic syndrome. J Physiol Pharmcol 64: 281-288, 2013.
32. Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol 113: 1593-1598, 2014.
33. Dzien A, Winner H, Theurl E, Dzien-Bischinger C, Lechleitner M. Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between <60 and >75 years. Obes Facts 6: 9-16, 2013.
34. Belalcazar LM, Raghavan VA, Ballantyne CM. Statin-induced diabetes: will it change clinical practice? Diabetes Care 32: 1941-1943, 2009.
35. Bhatia L, Byrne CD. There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evid Based Med 15: 84-85, 2010.